Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]

2270 reported adverse events

Drugs of this class: DAPRODUSTAT VADADUSTAT

These side effects are most commonly reported by patients taking drugs of the Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] class:

# Side effect Count
0 HOSPITALISATION 301
1 OFF LABEL USE 182
2 PRODUCT USE ISSUE 163
3 DEATH 135
4 HAEMOGLOBIN DECREASED 119
5 CARDIAC FAILURE 105
6 RENAL IMPAIRMENT 102
7 HAEMOGLOBIN INCREASED 91
8 DYSPHAGIA 83
9 MARASMUS 77
See all common reactions for Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]

Drugs of the Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 NEUROENDOCRINE CARCINOMA OF THE OESOPHAGUS 1 0.2500
1 CYLINDRURIA 2 0.2000
2 BENIGN NEOPLASM OF CHOROID 1 0.1429
3 ARTIFICIAL BLOOD VESSEL OCCLUSION 1 0.1250
4 PERIPHERAL VEIN STENOSIS 1 0.1250
5 OBTURATOR HERNIA 1 0.1250
6 MEDIASTINAL LYMPHADENECTOMY 1 0.1250
7 ERYTHROPOIETIN DEFICIENCY ANAEMIA 1 0.1111
8 CAMPYLOBACTER SEPSIS 3 0.0938
9 PERIPHERAL ARTERIAL REOCCLUSION 1 0.0909
See all enriched reactions for Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]